Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q3 2014 Earnings Presentation

33 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 6, 2014

  1. Slide 1: Third Quarter 2014 Corporate Update and Financial Results

    Third Quarter 2014 Corporate Update and Financial Results November 6, 2014 ¢ Fee ives TT

  2. Slide 2: Silvia Taylor, Senior VP Investor Relations

    Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications ¢ SUCAMPO The Science of Innovation v

  3. Slide 3: Agenda

    Agenda Introductions and Forward-Lookin: | Hl ig | ivi Statements Silvia Taylor | Corporate Update Peter Greenleaf | Pipeline Update Peter Lichtlen, M.D., Ph.D | Financial Performance Cary J. Claiborne } Closing Remarks Peter Greenleaf ¢ SUCAMPO : é ‘The Science of Innovation

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements This pr n “forward-looking " as that term is defined in the Private Securities igation Reform Act of 1995. These st: are based on managi 's current ex; ions and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statem

  5. Slide 5: Corporate Update

    14 Corporate-Update Peter Greenleaf Chief Executive Officer e ? SUCAMPO The Science of Innovation

  6. Slide 6: Q3 Key Highlights

    Q3 Key Highlights 1. Continued strong financial performance 2. Significant progress in securing AMITIZA growth 3. Focused our efforts and strengthened organizational capabilities 4. Increasing focus on pipeline development we SUCAMPO The Science of Innovation

  7. Slide 7: Continued Strong Financial Performance

    Continued Strong Financial Performance Significant gains drove strong financial performance * Solid execution against our strategy + Raising full year 2014 guidance for net income excluding special items to $15 - $20M and earnings per share excluding special times to $0.35 - $0.45 per diluted share

  8. Slide 8: Resolution of Our Patent Litigation

    Resolution of Our Patent Litigation Resolved patent litigation on AMITIZA with Par Pharmaceuticals Received a Paragraph IV notice letter regarding an ANDA submitted by Dr. Reddy’s Laboratories + Will continue to vigorously defend IP of AMITIZA we SUCAMPO . ‘The Science of innovation

  9. Slide 9: Improving and Strengthening Partnerships

    Improving and Strengthening Partnerships Strengthened Partnership with Takeda + Signed a global license, development, commercialization and supply agreement for AMITIZA for all global markets except Japan and China + Amended our existing collaboration and license agreement covering North America Neg

  10. Slide 10: Global AMITIZA Approvals and Regulatory Filings

    Global AMITIZA Approvals and Regulatory Filings MRP in Europe cic UK. Canada CIC and OIC CIC 012) i (started 10/31/14) 3 Switzerland CIC (2009) OIC (2014) Us. CIC (2006) IBS-C (2008) OIC (2013) Latin America TBD Takeda has rights to all markets except Japan (Abbott) and China $ SUCAMPO The Sei

  11. Slide 11: Proven and Experienced Management Team

    Proven and Experienced Management Team Corwen idl Homo Astrazeneca centocor eter Kiener, D.Phil Ambrx Se BLE ORE? Bristol-Myers Squibb idl Zyngenia ‘Peter Lichtlen, M.D., Ph.D. Chief Medical Oicer | Alcon ESBATech Matthias Alder Expanded Management CYTOS micr@met Cooley Team with or BATH Considerabl

  12. Slide 12: Clinical Development Strategy - Update

    Clinical Development Strategy - Update Clinical Development is Company’s Core Focus + Assessed each pipeline asset: scientific, regulatory, and commercial criteria + Decisions made on each asset's development plan + Shortened time to market across all compounds + Increased transparency around pipeli

  13. Slide 13: Peter Lichtlen, M.D., Ph.D., Chief Medical Officer

    Peter Lichtlen, M.D., Ph.D. Chief Medical Officer SUCAMPO The Science of Innovation AS

  14. Slide 14: Accelerating Additional Formulations for AMITIZA

    Accelerating Additional Formulations for AMITIZA Strong Partnership is Key to Success * Takeda funding 100% of costs for alternate formulation work, 70% of costs for pediatric functional constipation program Development Timeline: Lubiprostone — Alternate Formulation + Phase 3: 2H 15 | Oe PFC Phase 3

  15. Slide 15: Cobiprostone for NERD (Non-Erosive Reflux Disease)

    Cobiprostone for NERD {Non-Erosive Reflux Disease) NERD + Subtype of gastro-esophagael reflux disease (GERD) + Will begin a development program for cobiprostone to treat NERD * ~7-18 million PPI - refractory NERD patients in North America Fatroanoe gd Flas Lim Faire on PP gd 20% Development Timeline

  16. Slide 16: Cobiprostone for Oral Mucositis

    Cobiprostone for Oral Mucositis Oral Mucositis + Oral mucositis is a debilitating side effect of radiation therapy and chemotherapy + Causes large ulcers inside an individual's mouth Development Timeline: + Phase 2: 1H 15 + Phase 3: 1H 17 + Regulatory Filing: 2H 18 + Regulatory Approval: 2H 19 e 9 S

  17. Slide 17: Ion Channel Activator for Lumbar Spinal Stenosis

    lon Channel Activator for Lumbar Spinal Stenosis (LSS) Lss + Degenerative change in lumbar spine; unmet medical need with limited treatment options globally + More than 400,000 Americans, most >60 years of age, may be suffering from symptoms caused by lumbar spinal stenosis + Will move forward with

  18. Slide 18: Unoprostone Isopropyl for Retinitis Pigmentosa

    tapprostone Isopropyl for Retinitis Pigmentosa Retinitis Pigmentosa + Caused by gene mutations (variations) inherited from one or both parents + Begins with degeneration of rods, followed by progressive and irreversible death of cones leading to blindness. + RP affects about 1.5 million people world

  19. Slide 19: Unoprostone Isopropyl for Geographic Atrophy

    Unoprostone Isopropyl for Geographic Atroph (GAY! Age Related cult Geconcraton (AMD) Geographic Atrophy / Age Related Macular Degeneration + Dry AMD is the most common type of age related macular degeneration + More than a million patients are suffering from its advanced form, geographic atrophy, in

  20. Slide 20: At-A-Glance: Sucampo Pipeline

    At-A-Glance: Sucampo Pipeline CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT COMPLETED WIN PROGRESS / PROJECTED START ¢ > SUCAMPO 20

  21. Slide 21: Diversify Our Science

    Diversify Our Science Commenced external assessment of new therapeutic areas and targets + Build from our core in ophthalmology and GI * Consider both early and mid-to-late stage assets we SUCAMPO The Science of Innovation

  22. Slide 22: Financial Performance

    14 Performance-Update Cary J. Claiborne Chief Financial Officer é > SUCAMPO The Science of Innovation

  23. Slide 23: Financial Performance ($M, Excluding Special Items)

    ce ($M, Excluding)Special $0.20 $8.6 $6.3 Q3-14 YTD-14 Q3-14 YTD-14 Net Income EPS SUCAMPO = The Science of Innovation we

  24. Slide 24: Financial Performance ($M, GAAP Earnings)

    ial Performance ($M, GAAP Earnings) $0.09 $3.8 | | _ $1.5 $0.03 j — a, : Q3-14 YTD-14 Q3-14 YTD-14 Net Income EPS ¢$ sucAMPO 24 @ The Sstenes ol mension

  25. Slide 25: U.S. Net Sales ($M)

    S. Net Sales* ($M) AMITIZA a Q3-13 Q3-14 YTD-2013 YTD-2014 Driven by 4% TRx Growth & ¢ SUCAMPO 25 ha ic) Ta or ay sakura é The Science of innovation

  26. Slide 26: Q3 Revenue Highlights ($M)

    Q3 Revenue Highlights ($M) +118% Q3-13 Q3-14 Q3-13 Q3-14 Q3-13 Q3-14 Product Royalty Product Sales Total Revenue Revenue Revenue $ sucampo 28 The Science of Innovation

  27. Slide 27: Year-to-Date Operating Expenses

    $18.6 25%) = $16.0 $14.5 $14.7 hee $11.5 $9.5 : YTD-13 YTD-14 YTD-13 YTD-14 YTD-13 YTD-14 YTD-13 YTD-14 Cost of Goods R&D Expenses G&A Expenses S&M Expenses Sold e y ? SUCAMPO The Science of Innovation

  28. Slide 28: Updated Financial Guidance

    Updated Financial Guidance Updated 2014 Financial Guidance Net Income Excluding Special Items $15 - $20M EPS Excluding Special Items $0.35 - $0.45 SUCAMPO = The Science of Innovation we

  29. Slide 29: Peter Greenleaf, Chief Executive Officer

    Peter Greenleaf Chief Executive Officer SUCAMPO The Science of Innovation AS

  30. Slide 30: Upcoming Milestones

    Upcoming Milestones Expected Tg Global partnership agreement ¥ Update on AMITIZA alternate formulation and PFC development v File AMITIZA (CIC and OIC) for approval in Canada y Initiate MRP to secure approval for AMITIZA (CIC) in additional European markets q Decision on ion channel activator progra

  31. Slide 31: Vision: Globally, Fully Integrated Pharmaceutical Company

    ision: Globally, Fully Integrated aceutical Company. We will continue to execute on our strategy Secure The Foundation Seated Build The Growth Platform = Strengthen our overall capabilities = Secure AMITIZA franchise and drive = Advance AMITIZA Tite cycle management global growth 2 ppumize a ' inves

  32. Slide 32: o

    o 2 SUCAMPO The Science of Innovation

  33. Slide 33: References

    References Radiograph from Borowitz - Pediatric Constipation article on Medscape website; accessed 09.19.13, 2. Data from US Census Bureau website (http /factfinder2, census qovifacesitableservicesiisflages/productview xhtmI?sre=bkmk) 3, Sucampo data on file 4. Trott Aet al. Mucositis incidence, sev

Sucampo Pharmaceuticals — Q3 2014 Earnings Presentation on 6ix